SEC Company Response from Akero Therapeutics, Inc. (AKRO) (CIK 0001744659) — Jul 6, 2020
Akero Therapeutics, Inc. (AKRO) (CIK 0001744659)
Date: July 6, 2020 · CIK: 0001744659 · Accession: 0001104659-20-080872
AI Filing Summary & Sentiment
File numbers found in text: 333-239685
Letter
Re: Akero Therapeutics, Inc.
VIA EDGAR
July 6, 2020
United States Securities and Exchange Commission Division of Corporation Finance
Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549
Attention: Courtney Lindsay
Acceleration Request for Registration Statement on Form S-1 (File No. 333-239685)
Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Akero Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 7, 2020, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling John M. Mutkoski at (617) 570-1073. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: John M. Mutkoski, by facsimile to (617) 801-8731.
If you have any questions regarding this request, please contact John M. Mutkoski of Goodwin Procter LLP at (617) 570-1073.
Sincerely,
AKERO THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR July 6, 2020 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Courtney Lindsay Re: Akero Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 (File No. 333-239685) Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Akero Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 7, 2020, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling John M. Mutkoski at (617) 570-1073. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: John M. Mutkoski, by facsimile to (617) 801-8731. If you have any questions regarding this request, please contact John M. Mutkoski of Goodwin Procter LLP at (617) 570-1073. Sincerely, AKERO THERAPEUTICS, INC. /s/ Andrew Cheng Andrew Cheng, M.D., Ph.D. President and Chief Executive Officer Cc: Andrew Cheng, President and Chief Executive Officer, Akero Therapeutics, Inc. Jonathan Young, Chief Operating Officer, Akero Therapeutics, Inc. John Mutkoski, Esq., Goodwin Procter LLP Sam Zucker, Esq., Goodwin Procter LLP